Anti-interferon alpha antibodies and autoantibodies in patients with Beh double dagger et's disease uveitis treated with recombinant human interferon alpha-2a


Aydinoglu-Candan O., Araz-Ersan B., Gül A., Badur S., Tugal-Tutkun I.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.253, no.3, pp.457-465, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 253 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.1007/s00417-014-2856-3
  • Journal Name: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.457-465
  • Keywords: Behcet's disease, Interferon, Anti-interferon alpha antibody, Binding antibody, Autoantibody, CHRONIC HEPATITIS-C, LONG-TERM EFFICACY, BEHCETS-DISEASE, MULTIPLE-SCLEROSIS, AUTOIMMUNE-DISEASE, NEUTRALIZING ANTIBODIES, BETA ANTIBODIES, THERAPY, SAFETY, PANUVEITIS
  • Istanbul University Affiliated: Yes

Abstract

Recombinant human (rh) interferon alpha2a (IFN-alpha 2a) therapy is successfully used for the treatment of Beh double dagger et's disease (BD) uveitis refractory to conventional immunosuppressive treatment.